Denny's Corp. Oct 11

  • ID: 1929373
  • October 2011
  • Standard & Poors
1 of 3

Relatively well-known brand name; and Established market position. Participation in the highly competitive restaurant industry; Erratic sales performance; Weak cash flow protection measures; and Significant debt burden. The ratings on Denny's Corp. reflect Standard & Poor's Ratings Services' expectation that its credit metrics will remain adequate for the current rating as the company continues to pay down debt and benefits from its refranchising program. We assess the company's financial risk profile as aggressive, though it continues to strengthen its balance sheet, having repaid about $20 million of debt during the first two quarters of fiscal 2011. However, we anticipate that a difficult operating environment, still-high unemployment, and increasing commodity costs will weigh on profitability for the remainder of 2011. As...

Companies mentioned in this report are: Denny's Corp.
Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

Denny's Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.